DAVID GRAHAM to Ibuprofen
This is a "connection" page, showing publications DAVID GRAHAM has written about Ibuprofen.
Connection Strength
0.615
-
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial. Authors' reply. Aliment Pharmacol Ther. 2018 06; 47(11):1546-1547.
Score: 0.148
-
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018 06; 47(11):1453-1463.
Score: 0.147
-
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 12 29; 375(26):2519-29.
Score: 0.133
-
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009 Apr; 157(4):606-12.
Score: 0.078
-
Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial. Am J Gastroenterol. 2018 07; 113(7):1053-1054.
Score: 0.037
-
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis Rheumatol. 2018 04; 70(4):537-546.
Score: 0.037
-
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017 Nov 21; 38(44):3282-3292.
Score: 0.036